China CDMO WuXi Biologics has picked Ireland for its first biologics plant outside of China, a facility in which it will invest €325 million.
Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.
Takeda and Shire struck a buyout deal worth $64B; Nektar and Takeda teamed up for a combo cancer trial; and more.
We have a deal. Late on Tuesday, Shire said Takeda had finally landed on a buyout offer—£49 per share—worth recommending to shareholders.
Takeda may just go unchallenged after all in its quest to swallow Shire—and more cash on the table may be the clincher.
Shire nixed Takeda's $60 billion-plus buyout offer, Hanmi ditched lung cancer hopeful olmutinib, Grail is looking for $1 billion before Hong Kong IPO.
Just a few hours after Allergan confirmed that it was in buyout talks for hot target Shire, it said it didn’t intend to make an offer.
Shire has already rebuffed Takeda three times, and now the Japanese drugmaker faces a competing bidder—Allergan.
The FDA issued a warning letter to Hong Kong-based over-the-counter drugmaker Luen Wah Medicine, citing the company for not testing the identity and strength…
Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.